Findings

What do systematic reviews say?

4 questions · 4 findings · 3 reviews · Breast Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 25%Low 2 · 50%Moderate 1 · 25%High 0 · 0%

Surgery vs primary endocrine therapy

Survival ‐ overall · Women (70 years plus) with operable primary breast cancer

Surgery showed no clear difference in survival ‐ overall compared with primary endocrine therapy (low certainty).

1 finding from 1 review

Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus) 2014 · Cochrane Headline outcomes only
HR 0.98 [0.81, 1.2]
3 studies · 495 participants
Low

Surgery plus endocrine therapy vs primary endocrine therapy

Survival ‐ overall · Women (70 years plus) with operable primary breast cancer

Surgery plus endocrine therapy showed no clear difference in survival ‐ overall compared with primary endocrine therapy (low certainty).

1 finding from 1 review

Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus) 2014 · Cochrane Headline outcomes only
HR 0.86 [0.73, 1]
3 studies · 1076 participants
Low

Breast surgery plus systemic treatment vs systemic treatment

Overall survival at 2 years · people with metastatic breast cancer

It is very uncertain whether breast surgery plus systemic treatment changes overall survival at 2 years compared with systemic treatment (very low certainty).

1 finding from 1 review

Breast surgery for metastatic breast cancer 2018 · Cochrane Headline outcomes only
HR 0.83 [0.53, 1.31]
2 studies · 624 participants
Very low

Boost vs no boost

Overall survival: mortality at 5 years · breast‐conserving radiotherapy for breast cancer

Boost showed no clear difference in overall survival: mortality at 5 years compared with no boost (moderate certainty).

1 finding from 1 review

Tumour bed boost radiotherapy for women after breast‐conserving surgery 2017 · Cochrane Headline outcomes only
HR 1.04 [0.94, 1.14]
2 studies · 6342 participants
Moderate